Myriad Genetics
MYGN
186 hedge funds and large institutions have $1.33B invested in Myriad Genetics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 69 increasing their positions, 71 reducing their positions, and 17 closing their positions.
2,543% more call options, than puts
Call options by funds: $6.9M | Put options by funds: $261K
1.6% more ownership
Funds ownership: 99.4% → 101% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1% less funds holding
Funds holding: 187 → 186 (-1)
3% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 71
29% less capital invested
Capital invested by funds: $1.88B → $1.33B (-$553M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$49M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.78M |
| 4 |
EARNEST Partners
Atlanta,
Georgia
|
+$4.18M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$22M |
| 2 |
BlackRock
New York
|
-$9.09M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$6.54M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$3.85M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.49M |
MYGN Hedge Fund Activity: Q3 2023 in Review
186 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2023, worth a combined $1.33B — down 29% from $1.88B a quarter earlier.
Fund positioning in MYGN was balanced in Q3 2023: 17 funds opened new positions, 17 closed out, 69 added to existing stakes and 71 trimmed.
The largest buyer was Millennium Management, adding an estimated $49M. The largest seller was Balyasny Asset Management, cutting an estimated $22M.
- 186 institutional investors held Myriad Genetics (MYGN) as of Q3 2023, down from 187 in Q2 2023.
- Funds reported $1.33B of Myriad Genetics stock for Q3 2023, down 29% quarter-over-quarter.
- 17 funds opened new Myriad Genetics positions in Q3 2023 and 17 closed out, a net change of 0 holders.
- The largest Myriad Genetics buyer in Q3 2023 was Millennium Management, an estimated $49M added.
- The largest Myriad Genetics seller in Q3 2023 was Balyasny Asset Management, an estimated $22M sold.
Based on aggregated 13F filings for Q3 2023.